Hollis-Eden news from FierceBioResearcher
NewsHollis-Eden spurs stock price with preclinical news
It's not often that you see a set of preclinical data influence a company's stock price, but Read more...
| Press ReleasesPRESS RELEASE: Hollis-Eden Pharmaceuticals Presents Positive Results with Novel Drug Candidate HE3235 Hollis-Eden Pharmaceuticals Presents Positive Results with Novel Drug Candidate HE3235 in Model of Hormone Independent Prostate Cancer SAN DIEGO -- Oct 4, 2007 - Hollis-Eden Pharmaceuticals the Read more... PRESS RELEASE: Hollis-Eden Pharmaceuticals Presents HE3235 Update at ASCO Breast Cancer Symposium Hollis-Eden Pharmaceuticals Presents HE3235 Update at ASCO Breast Cancer Symposium Preclinical Data Show Lasting Anti-Tumor Effect of Novel Drug Candidate SAN DIEGO -- Hollis-Eden Pharmaceuticals, Read more... |
Get more Hollis-Eden coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends